Navigation Links
ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting

Three Developmental Compounds Show Early Promise

MONTREAL, April 17 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced results of three compounds in preclinical studies for prostate and pancreatic cancer at the American Association for Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this week.

Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions as follows:

Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed significant antitumor activity in human prostate cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01).

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, presented preclinical data on the PBI-0110 alone and in combination with gemcitabine in intradermal and orthotopic pancreatic cancer. The study showed that PBI-0110 alone significantly inhibited pancreatic tumor growth in mouse models by as much as 58 percent (p < 0.05) after 44 days. The study also demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg dose being the most effective, inhibiting growth by nearly 40 percent after 25 days (p < 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabine demonstrated similar efficacy. Finally, the study demonstrated increased survival in mice that received the combination therapy of PBI-0110 200mg/kg and gemcitabine.

Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented data on PBI-1308, which demonstrated a reduction of inflammation and cancer cell proliferation through inhibition of NF-kappaB in prostate cancer and inhibition of TNF-alpha, and inflammatory cytokine.

"We continue to be very proud of the progress our compounds are making in early-stage cancer research," said Pierre Laurin, president and CEO of ProMetic Life Sciences, Inc. "We are assembling a broad pipeline of promising candidates for various cancers, which augments PBI-1402, our lead compound which has shown compelling human data for the treatment of chemotherapy-induced anemia."

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
7. Prometic to present at the American Chemical Society
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial processes, the ... in-line sensors can represent a weak spot where leaking process media is a ... sensor housings , which are designed to tolerate extreme process conditions. They combine ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):